Project 2: Astrocyte-related molecular mechanisms underlying altered neuronal plasticitv in Down syndrome The goal of this project is to understand the molecular mechanisms associated with abnormal astrocyte function and their role in altered structural and functional plasficity in the Down's syndrome (DS) brain. Astrocytes are critical regulators of neuronal stem cells (NSCs) proliferation and differentiafion as well as dendritic spine development and synaptogenesis. We found metabolic deficits in DS astrocytes directly associated with reduced NSCs viability and aberrant spine formation. To investigate the molecular pathways associated with abnormal astrocyte function and its role in DS altered structural and functional neuroplasticity we propose: 1. To identify the molecular alterations in OS astrocytes responsible for impaired NSCs neurogenesis and spine pathology. We will define the role of intracellular AU and mitochondrial dysfunction in astrocyte secretory deficits, and the role of reduced APPs and thrombospondin 1 (TSP-1) secrefion in NSCs and spine pathology. 2. To analyze the effectiveness of mitochondrial cofactors and B-secretase inhibitors to prevent or revert DS astrocyte secretory deficits and concomitant NSCs and spine alterations. 3. A) To study the relation between astrocyte alterations, neurogenesis and spine anomalies in DS brains. We will generate normative data on the associafion between astrocyte alterations and NSCs and spine deficits in DS individuals. B) To assess the usefulness of TSP-1 levels in CSF and plasma as a biomarker of AD. We propose to perform preliminary studies to evaluate the usefulness of TSP-1 levels in plasma and CSF as a biomarker of AD in sporadic AD and DS+AD pafients. We will take advantage of our extensive experience culturing primary human nerve cells derived from fetal brain tissue. NSCs cultures in the form of neurospheres, pure astrocyte cultures, and cocultures of rat hippocampal neurons growing on top of human astrocytes (normal and DS) will be utilized for aims 1 and 2.
Aim 3 will utilize post-mortem brain samples and CSF and plasma samples provided by the Neuropathology Core. The Stafistical Core will provide feedback in all statistical procedures.
These experiments will gather a wealth of information on novel aspects of DS structural and functional plasticity, which may be closely associated with the early and rapid transition to AD that occurs in most individuals with DS. We expect to identify novel therapeutic targets to treat neurodegeneration and cognitive decline not only in older DS individuals but also in the larger population affected by sporadic AD.
|John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the Î´ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960|
|Bonham, Luke W; Geier, Ethan G; Fan, Chun C et al. (2016) Age-dependent effects of APOE Îµ4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol 3:668-77|
|Paganini-Hill, Annlia; Kawas, Claudia H; Corrada, Maria M (2016) Lifestyle Factors and Dementia in the Oldest-old: The 90+ Study. Alzheimer Dis Assoc Disord 30:21-6|
|Ting, Simon Kang Seng; Hao, Ying; Chia, Pei Shi et al. (2016) Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease. Sci Rep 6:20858|
|Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93|
|Grill, Joshua D; Zhou, Yan; Elashoff, David et al. (2016) Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging 39:147-53|
|Chapman, Kimberly R; Bing-Canar, Hanaan; Alosco, Michael L et al. (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther 8:9|
|Fischer, Corinne E; Qian, Winnie; Schweizer, Tom A et al. (2016) Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. J Alzheimers Dis 50:283-95|
|Leal, Stephanie L; Noche, Jessica A; Murray, Elizabeth A et al. (2016) Positivity effect specific to older adults with subclinical memory impairment. Learn Mem 23:415-21|
|Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717|
Showing the most recent 10 out of 383 publications